RxDoctor Payments Data

Heather Holahan, MD

Dermatology · Concord, NCNPI 1912387143

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (50.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by UCB, Inc. at 50.8% of the total. 2025 is the largest year on record at $30,854, more than ten times the $80 reported in 2021. Among dermatology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$46,470in general payments, 2019–2025

Across 215 payments — averaging $216.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$24K
  • Novartis$20K
  • AbbVie$726
  • Johnson & Johnson$722
  • Galderma Laboratories, L.p.$268
  • Sanofi$195
  • plus $701 from 8 others

What the payments were for

  • Consulting fees$23,22550%
  • Speaking & faculty fees$14,89632%
  • Travel & lodging$3,0517%
  • Food & beverage$5,01911%
  • Education$2791%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,470 in reported general payments places this provider in the 90th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$156,381
Medicare patients
437
Services billed
2,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$232,350
Enbrel SureclickEtanercept16$196,887
Dupixent PenDupilumab28$139,390
OtezlaApremilast14$67,283
ErtapenemErtapenem Sodium14$7,605
Clobetasol Propionate75$5,316
Tacrolimus17$3,775
Fluorouracil39$2,877
Tretinoin31$2,036
Ketoconazole116$1,805
Betamethasone Dipropionate24$1,307
Fluocinonide38$1,288
Triamcinolone Acetonide124$1,232
Clindamycin Phosphate34$1,162
Metronidazole24$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$70$67,28314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →